An Introduction to Preventive Cardiology
Preventive cardiology covers all aspects of the prevention and lowering the risk of cardiovascular heart diseases and their complications, including reducing the risk of heart attacks and strokes. Consisting of primary and secondary prevention, preventive cardiology aims to reduce incidence and mortality stemming from diseases such as ischaemic heart disease. Methods to evaluate patient risks of developing cardiovascular diseases or suffering cardiovascular events, including examination of lifestyle and hereditary factors, other pre-existing conditions, cardiac imaging, diagnostic tests and more, can be used to identify patients who are most at-risk and provide multidisciplinary risk intervention to mitigate those risks and achieve heart-healthy lifestyles for patients.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Preventive Cardiology Content
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
- Identify the epidemiological and pathophysiological drivers behind the progression of CKD
- Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
- Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias
- Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
- Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
- Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
Peter Toth shares his highlights from the ASPC 2022 Congress on CVD Prevention!
Dr Peter Toth (President of the American Society for Preventive Cardiology [ASPC]) shares his highlights from the 2022 Congress on CVD Prevention. Find out more about the importance of the A, B, Cs of preventive cardiology and personalized patient care. Questions What were your highlights of the ASPC 2022 Congress on CVD Prevention? (00:15-00:52) 2. […]
Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease
Heart International. 2021;15(1):14-19 DOI: https://doi.org/10.17925/HI.2021.15.1.14
Peripheral artery disease (PAD) is a severe manifestation of systemic atherosclerotic disease that commonly refers to lower-extremity arterial involvement. The global burden of PAD is estimated to involve over 200 million patients, with prevalence increasing by 24% over the past decade.1 In contrast to myocardial infarction and stroke, which are declining in the USA, the […]
Use of Coronary Computed Tomography for Calcium Screening of Atherosclerosis
Heart International. 2020;14(2):76-9 DOI: https://doi.org/10.17925/HI.2020.14.2.76
Cardiovascular disease (CVD) represents the prevailing cause of death in the United States.1 Cancer, accidents and other prevalent causes of death, have a multitude of pathophysiologic and mechanistic underpinnings leading to mortality. Meanwhile, the majority of CVD is primarily attributable to atherosclerosis.2 Moreover, the degree of coronary calcification strongly correlates with the magnitude of atherosclerotic plaque burden, […]
Kazem Rahimi, ESC 2020 – Blood Pressure Lowering for Prevention of Cardiovascular Events
We spoke to Dr Kazem Rahimi (Oxford University, Oxford, UK) about the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC) and their recent study examining blood pressure lowering to prevent cardiovascular events. Questions Could you tell us a little about the Blood Pressure Lowering Treatment Trialists Collaboration (BPLTTC) and its objectives? (0.13) Could you give us […]
Cardiovigilance in Atrial Fibrillation – Primordial to Quinary Prevention Intervention
European Journal of Arrhythmia & Electrophysiology. 2019;5(2):77–81 DOI: https://doi.org/10.17925/EJAE.2019.5.2.77
Long-term follow-up of patients with atrial fibrillation (AF) has confirmed a significant increase in cardiovascular events, long-term risk of stroke, heart failure and all-cause mortality (89% in those with AF compared to 27% in those without AF).1 Not only is AF associated with a five-fold increased risk of stroke, AF-related stroke is also likely to […]
48/Application of the MADIT ICD Benefit Score to a tertiary UK centre primary prevention population
European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr48
Introduction: Guidelines recommend the implantation of primary prevention defibrillators (pICD) in patients with a left ventricular ejection fraction (LVEF) of <35% due to the associated higher risk of ventricular arrhythmias (VA) in this cohort. However, reported incidence of VA in this cohort is only 5–10%/year with many deaths occurring prior to VA events and up […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!